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ABSTRACT 
The human digestive system is colonized by a huge number of microorganisms, that are referred 
to collectively as the gut microbiota. The composition of intestinal microorganisms are shaped from an 
early life and undergoes constant changes depending on the influence of external factors, such as: type 
of delivery, feeding the young child, diet in subsequent years of life, pharmaceuticals use, stress, lifestyle 
or infections and previous inflammation within the digestive tract. Despite transient changes in 
microbiota composition, the intestinal ecosystem is constantly striving to maintain homeostasis, both 
qualitative and quantitative, which is fundamental to human health and human development. Microbes 
present in the intestines are responsible for sealing the intestinal barrier, mucin production, stimulation 
of the angiogenesis process, supporting digestive processes by fermentation and decomposition of 
undigested food residues, vitamin production or protection from pathogenic microorganisms. As shown 
by numerous studies carried out in recent years, intestinal dysbiosis plays a fundamental role in the 
development of many chronic diseases such as inflammatory bowel disease, diabetes, obesity, celiac 
disease, connective tissue diseases and others. Insightful understanding of the interactions between 
microorganisms and the host organisms can provide new information about pathogenesis of diseases as 
well as new ways to prevent and treat intestinal or systemic disorders. The aim of this work is to review 
the latest reports on the role of the gastrointestinal microbiome in selected chronic diseases. 
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1.  INTRODUCTION 
 
The human digestive system is colonized by a huge number of microorganisms, that are 
referred to collectively as the gut microbiota. More than 99% of natural gastrointestinal 
microbiota are 4 types of microorganisms: Bacteroidetes (24%), Firmicutes (64%), 
Actinobacteria (3%) and Proteobacteria (8%), among which the following types predominate: 
Bifidobacterium, Lactobacillus, Streptococcus, Bacteroides or Enterobacteriaceae [1]. Besides 
bacteria, the composition of intestinal microbiota including slightly less numerous populations 
of fungi, viruses, archaea or protozoa. The composition of intestinal microorganisms are shaped 
from an early life and undergoes constant changes depending on the influence of external 
factors, such as: type of delivery, feeding the young child, diet in subsequent years of life, 
pharmaceuticals use, stress, lifestyle or infections and previous inflammation within the 
digestive tract [2]. Despite transient changes in microbiota composition, the intestinal 
ecosystem is constantly striving to maintain homeostasis, both qualitative and quantitative, 
which is fundamental to human health and human development [3].  
Microbes present in the intestines are responsible for sealing the intestinal barrier, mucin 
production, stimulation of the angiogenesis process, supporting digestive processes by 
fermentation and decomposition of undigested food residues, vitamin production or protection 
from pathogenic microorganisms [4]. They also play a key role in the modulation of the host's 
immune response which is mediated through Toll-Like Receptors (TLR) and Nucleotide 
Oligomerization Domain (NOD). The correct series of interactions between the 
microorganisms and cells of the gut lymphoid tissue - GALT (Gut Associated Lymphoid 
Tissue) is the basis for the development of appropriate tolerance to ubiquitous commensal 
bacteria and food antigens delivered to the body every day [5].  
The effects of interactions between humans and their intestinal microbiome are not only 
related to the functioning of the gastrointestinal tract, but can also influence other processes and 
organs, therefore the disturbance of microbiota composition called dysbiosis can have serious 
health implications. When one of the stages of this delicate interaction fails, it may result in the 
occurrence of autoimmune or inflammatory diseases [5].  
As shown by numerous studies carried out in recent years, intestinal dysbiosis plays a 
fundamental role in the development of many chronic diseases such as inflammatory bowel 
disease (IBD), diabetes, obesity, connective tissue diseases and others [6-10]. Insightful 
understanding of the interactions between microorganisms and the host organisms can provide 
new information about pathogenesis of diseases as well as new ways to prevent and treat 
intestinal or systemic disorders.  
The aim of this work is to review the latest reports about role of the gastrointestinal 
microbiome in selected chronic diseases. 
 
 
2.  INTESTINAL MICROBIOTA AND OBESITY 
 
In recent years, there have been many studies on the potential link of intestinal 
microorganisms with the development of obesity [11-16]. There are several mechanisms 
explaining the interaction between microbiome and host metabolism that may contribute to the 
development of this disease. Intestinal microbiota plays an important role in intestinal mucosal 
permeability, and metabolic activity of microorganisms is crucial meaning in obtaining calories 
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from digested food, absorption of polysaccharides, as well as in the process of fat accumulation 
in the host's fat tissue, which partly may explain the importance of microorganisms in the 
development of disorders related to excessive weight [17, 18]. Previous studies conducted with 
both animals and humans seem to confirm this hypothesis. 
Ley et al. showed that the gut of obese mice was characterized by a different bacterial 
colonization compared to rodents with normal body weight. Intestinal microbiota of overweight 
mice was characterized by a significantly increased number of Firmicutes, while the number of 
bacteria of the genus Bacteroides was reduced compared to rodents siblings with normal body 
weight. Moreover, the transfer of bacteria from the digestive tract of obese animals to germ-
free mouse, caused a significant increase in weight compared to mice which received intestinal 
bacteria from animals of normal body weight [11]. 
Similar dependencies about quantitative disorders in the intestinal microbiota within 
Bacteroides and Firmicutes are also found among humans [12-14]. It is assumed that this 
different composition may affect the difference in obtaining energy from digested food. These 
assumptions seem to confirm the fact that during studies conducted by Ley et al., it was 
observed that due to weight loss, the ratio of Bacteroides/Firmicutes increased to a degree 
depending on the percentage of mass reduction, while independent of the supply of calories 
[15]. Also Turnbaugh et al. using metagenomic and biochemical analysis, showed that intestinal 
microbiota of obese individuals was characterized by different metabolic capacity and obtained 
more energy from the supplied food than the microbiota of lean individuals [16]. Moreover, the 
transfer of intestinal microorganisms from obese individuals to the digestive system of animals 
with normal body mass, resulted in a significant body fat increase and weight gain compared 
to animals colonized with intestinal microbiota obtained from lean individuals [16, 19]. It is 
interesting to note that the fat content among conventionally reared mice was 40% higher than 
in germ-free animals, despite reduced food intake. Furthermore, the conventionalisation of 
germ-free mice with intestinal microbiota from the cecum of conventionally raised rodents, 
caused an 60% increase in fat content and the development of insulin resistance within 14 days 
despite a reduction in food intake [17]. 
These results seem to confirm the hypothesis that the composition of intestinal microbiota 
affects the amount of energy obtained from digested food, and furthermore it also promotes 
insulin resistance, an increase blood glucose and leptin levels and hypertrophy of adipocytes, 
which identifies intestinal microbiota as an important factor in etiology of obesity. 
 
 
3.  THE CONTRIBUTION OF INTESTINAL MICROORGANISMS TO  
     THE DEVELOPMENT OF TYPE 1 AND TYPE 2 DIABETES 
 
Until recently, it was thought that the main reason for the rapid increase in the number of 
patients suffering from diabetes is a change in eating habits and lifestyle. However, recent 
reports indicate, that intestinal microbes may play an equally important role in the pathogenesis 
of this disease [6, 20, 21]. More and more evidence shows that intestinal microorganisms 
determine the formation of metabolic disorders as a result of an abnormal gut barrier 
permeability as a results of inducing inflammation of low intensity [22, 23]. For some time 
now, it has been suggested that in patients with type 2 diabetes (T2DM), chronic low-grade 
inflammation with abnormal expression and production of many inflammatory mediators, such 
as tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) is associated with 
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lipopolysaccharide, which is an integral component of the Gram-negative cell membrane, 
whose increased concentration is found in patients with type 2 diabetes (T2DM) [23, 24]. It is 
supposed that this endotoxin induces excessive proinflammatory cytokine production, which is 
associated with an increased blood glucose level and connected with suppression of insulin 
signaling by inhibition of insulin receptor tyrosine kinase activity which contributes to the 
development of insulin resistance and the development of diabetes [20-22]. 
A study on mice confirmed a positive relationship between concentration of bacterial 
lipopolysaccharide in plasma and insulin resistance and type 2 diabetes [24]. The confirmation 
of this hypothesis may be the fact that the experiment consisting in prebiotic supplementation 
of leptin-deficient (ob/ob) mice, a model of type 2 diabetes, induced significant changes in 
microbiota, i.e. the increase number of bacteria of the genus Lactobacillus spp., 
Bifidobacterium spp. and Clostridium coccoides, which was correlated with improved glucose 
tolerance and reduction of low-grade inflammation. Lower plasma lipopolysaccharide and 
decrease level of inflammatory cytokines were also observed. Moreover, prebiotic-treated mice 
were characterized by a reduced expression of oxidative stress markers and metabolic changes, 
which was the result of improved tight-junction integrity due to changes in microbiota. Besides, 
the influence of the change in the composition of microorganisms on the increased production 
of gastrointestinal peptides: GLP-1, GLP-2, YY peptide, ghrelin (which are of key importance 
in the regulation of glucose homeostasis) were found [25, 26]. 
Studies involving people with T1DM and T2DM also demonstrated differences 
in the composition of their intestinal microbiota compared to healthy people. Larsen et al. 
showed that patients with T2DM were characterized by a significantly reduced number of 
Firmicutes, while microbes belonging to the class of Betaproteobacteria occurred in a 
significantly higher number. Moreover, number of these bacteria was correlated with blood 
glucose level. Positive correlation between Bacteroidetes/Firmicutes ratio and the 
Bacteroides/Prevotella proportion to the C.coccoides group/Eubacterium rectale with plasma 
glucose concentration was observed [27]. 
Also Salamon et al. showed that patients with T2DM are characterized by a reduced 
number of Firmicutes and an increased abundance within the group of Proteobacteria. 
Interestingly, the number of Bacteroidetes was different depending on the type of diabetes. 
Patients with type 1 diabetes (T1DM) were characterized by significantly increased 
colonization of the intestine by Bacteroidetes compared to the control group, whereas in group 
of people with T2DM, an opposite tendency was observed [28]. This is consistent with the 
studies carried out on the rat’s model, in which has been shown that the increase in the number 
of Bacteroidetes is correlated with T1DM [29]. 
Gosiewski et al. were one of the few, who attempt to show the relationship between fungal 
dysbiosis and the occurrence of diabetes. As a result, the researchers showed that among people 
with type 1 diabetes and type 2 diabetes the number of fungi of the genus Candida was a 
significantly higher compared to the healthy people (respectively: T1DM: 4.35×103 T2DM: 
9.13×104 vs. control group: 6.72×101) [30].  
While the above results show increased colonization of the intestine by fungi in diabetic 
patients, there are still too few studies of mycobiome to determine whether these changes are 
secondary effects of this disease resulting from elevated blood sugar level which create specific 
conditions for intensive colonization by fungi or maybe dysbiosis within the mycobiome 
contribute to the pathogenesis of the disease. 
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4.  CHANGES IN GUT MICROBIOTA ASSOCIATED WITH NEUROPSYCHIATRIC  
     DISORDERS 
 
The brain and the gut communicate to each other through the gut–brain axis. 
Communication between these organs has a two-way course and involves participation of 
endocrine, neuronal and immunological pathways [31]. Numerous scientific studies show that 
the composition of intestinal microbiota, through the secretion of abundant amount of 
neuroactive compounds and immunomodulatory substances, shapes the proper structure as well 
as functions of the brain regions involved in the regulation of anxiety, pain, cognitive ability or 
control of emotions and mood [31-33]. In addition, it is suggested that the microbiome is 
necessary for the normal gross morphology and ultrastructure of the amygdala and 
hippocampus [34]. Due to the documented impact on intestinal microbiota on the proper 
functioning and development of mental health, the role of intestinal dysbiosis in the 
development of neurodevelopmental or neurodegenerative disorders is postulated [35-37]. 
Previous studies including the analysis of the composition of intestinal microbiota people 
with neuropsychiatric diseases have shown that patients were characterized by disorders in the 
composition of the gastrointestinal microbiome. And so, people with autism were characterized 
by significantly lower number of bacteria of the genus Bifidobacterium, Prevotella, 
Coprococcus while numer of bacteria of the genus Lactobacillus, Clostridium and 
Bacteroidetes were increased [38-42]. It was also shown that children with autism were 
characterized by increased colonization by Clostridium difficile, which was positively 
correlated with the level of 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA), which is 
the main metabolite produced by numerous Clostridium species. It is a metabolite of m-tyrosine 
(3-hydroxyphenylalanine), which have influence the reduction of the level of brain 
catecholamines and blocks dopamine beta-hydroxylase, leading to excess dopamine and the 
development of abnormal behaviors and symptoms characteristic of autism in experimental 
animals (stereotypical behavior, hyperactivity and hyperreactivity) [43]. 
The gut microbiota of people with Alzheimer's disease (AD) shows a significantly higher 
number of Bacteroidetes and less Firmicutes, Actinobacteria and Bifidobacterium compared to 
the control group [44]. These observations have also been confirmed by studies involving the 
mouse model of Alzheimer's disease, which additionally showed a reduced colonization by 
Proteobacteria, Verrucomicrobia and an increased number of Tenericutes. Interestingly, the 
transplantation of intestinal microbiota from mouse model of AD into germ-free rodents, 
resulted in the formation of a beta-amyloid plaques in the brain, which is a characteristic 
symptom of AD development [45]. 
In recent years, there have been papers postulating that the participation in the 
pathogenesis of AD may have Porphyromonas gingivalis, which is listed among the probable 
etiological factors of periodontitis. The DNA of this bacterium was detected both in human 
brains among deceased patients who suffered from AD, as well as in the cerebrospinal fluid of 
living people with suspicion of this disease. In addition, in the samples taken from the brains of 
patients suffering from AD, the researchers also detected toxic enzymes secreted by these 
bacteria, known as gingipains. Their presence was associated with two different indicators of 
AD: abnormal tau protein and ubiquitin. Moreover, in further laboratory studies, oral 
administration of this pathogen to mice led to the colonization of animal brains by P. gingivalis 
and it was associated with increased production of beta-amyloid [46]. 
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Intestinal dysbiosis was also demonstrated in Parkinson's disease (PD) and it was 
manifested by increased number of Bacteroidetes, Enterobacteriaceae and the bacteria of the 
genus Ralstonia belonging to Proteobacteria. Decrease in the number of Faecalibacterium, 
Blautia, Coprococcus and Roseburia has also been documented [47]. Moreover, these dysbiosis 
have been associated with the induction of inflammation and abnormal folding of α-synuclein 
(α-syn) which is a presynaptic neuronal protein genetically and neuropathologically related 
with PD [47, 48]. 
In studies about pathophysiology of stress and anxiety, it was shown that the development 
of these disorders is favored by Campylobacter jejuni infection which influenced the induction 
of c-Fos protein - a marker of neuronal activation [49]. Goehler et al. showed that infection of 
mice (by supplying of 0.2 ml of the solution containing Campylobacter jejuni) affected the 
development of anxiety and behavioral disorders compared to control mice which received 
physiological saline solution [49]. Interestingly, the supply of probiotics containing 
Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus helveticus and Lactobacillus 
rhamnosus has been shown to alleviate anxiety and normalize animal behavior [50-54]. 
Dysbiosis occurring in the above disease entities may disturb the integrity and 
permeability of the intestinal barrier, consequently disrupting communication between the gut 
and the central nervous system. As a result, there is an increase level of antigens in the blood, 
which activates the secretion of inflammatory mediators which are able to penetrate blood-
brain barrier [55, 56].  
It has been shown that lipopolysaccharide present in the cell wall of gram-negative 
bacteria may affect the mood, as well as cognitive ability. It is possible through the present of 
receptors recognizing molecular bacterial patterns such as NOD or TLR located in the surface 
of glial cells or with the participation of indirect mechanisms associated with the activation of 
the immune response [56]. These disorders can initiate apoptosis of nerve cells and also 
contribute to the development of emotional disorders, cognitive limitations and other mental 
disorders [3, 35, 56, 57]. Furthermore, the microorganisms present in the gut are involved in 
the regulation of gene expression associated with myelination of prefrontal cortex, which is a 
key area involved in the development of disorders such as schizophrenia, depression and autism 
[58]. 
One of the first animal experiments regarding the effect of intestinal microbiota in the 
prevention of depression showed that supplementation of rats with the probiotic strain of 
Bifidobacterium infantis has an impact on the significantly increased production of tryptophan, 
a precursor of serotonin in the central nervous system (CNS). After supplementation, an 
increase concentration of kynurenine acid (which plays an important role in the functioning of 
the CNS) and reduction of the level of proinflammatory cytokines IFN-gamma, TNF-α and IL-
6 was also observed. The addition of bifidobacteria also resulted in the reduction of 5-
hydroxyindoleacetic acid (5-HIAA) (constituting the end product of transformation of 
tryptophan - a metabolite formed from deamination of serotonin) in the frontal cortex and 
reduction of 3,4-dihydroxyphenylacetic acid (DOPAC) in the amygdala. It was also associated 
with beneficial effect on changes in behavior [59]. 
Equally promising results of probiotic therapy to combat stress have been demonstrated 
by Liang et al. [60]. The study used a rat model of depression, in which rodents were subjected 
to chronic stress for 21 days. One of the tested group received the probiotic strain of 
Lactobacillus helveticus NS8 throughout the stress induction period and next rats were 
observed during behavioral tests. The results showed that probiotic supplementation reduced 
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chronic behavioral disorders caused by stress, such as anxiety or depression, and limited the 
development of cognitive dysfunction compared to the group of rats which did not receive a 
probiotic. Moreover, the supply of L. helveticus NS8 resulted in lower plasma corticosterone 
(CORT) and adrenocorticotropic hormone (ACTH) levels. Increase of plasma anti-
inflammatory interleukin-10 (IL-10) concentration, as also as higher hippocampal serotonin (5-
HT) and norepinephrine (NE) levels were also observed [60]. 
Probiotic combination of Lactobacillus and Bifidobacterium in model of post myocardial 
infarction (MI) depression has also been studied.  
Thus combination therapy with L. helveticus and Bifidobacterium longum eased 
depression after MI by reducing the concentration of proinflammatory cytokines, restoring 
intestinal barrier integrity and as well as by limiting apoptosis of nerve cells in the structures of 
the limbic system which is responsible for the central functions of emotion [61, 62] 
Bravo et al. showed the effect of lactic acid bacteria on changes in the gamma-
aminobutyric acid (GABA) receptor involved in the pathogenesis of anxiety and depression 
[51]. Mice supplementation with L. rhamnosus (JB-1) induced region-dependent changes in 
GABAB1b mRNA in the brain with increases in cortical regions and concomitant reductions 
in expression in the amygdala, hippocampus and locus coeruleus compared to control group.  
Moreover, L. rhamnosus (JB-1) reduced the expression of GABAAα2 mRNA in the 
prefrontal cortex and amygdala, and increased GABAAα2 in the hippocampus. In addition, this 
strain reduced the level of stress-induced corticosterone and limited the development of anxiety 
and depression-related behavior [51]. 
Other independent studies have also documented the role of microorganisms in the 
production and stimulation of the secretion of neurotransmitters and neuroactive compounds. It 
has been reported that the production of the inhibitory neurotransmitter GABA may be induced 
by the bacteria of the genus of Lactobacillus and Bifidobacterium, while Escherichia, Bacillus 
and Saccharomyces spp. are able to stimulate noradrenaline production. On the other hand, 
Candida, Streptococcus, Escherichia and Enterococcus spp. are capable to producing 
serotonin, and Bacillus is able to secrete dopamine. Some bacteria of the genus Lactobacillus 
spp. are also able to produce acetylcholine [63, 64]. These neurotransmitters synthesized by 
microorganisms are able to penetrate the intestinal mucosa and mediate the physiological 
functions of the brain and play a role in the pathophysiology of some psychiatric diseases, 
therefore the above data emphasize how important role in the two-way communication of the 
gut-brain axis are bacteria, and furthemore, they suggest that some microorganisms may prove 
to be useful therapeutic supplements in stress-related disorders 
 
 
5.  ASSOCIATION OF INTESTINAL MICROBIOME WITH CELIAC DISEASE 
 
Celiac disease is a serious autoimmune disease that occurs in genetically predisposed 
people who have DQ2 or DQ8 haplotypes encoding specific antigens in the HLA region. 
However, the genetic factor itself is insufficient to trigger clinical symptoms, which suggests 
the key role of environmental factors (including microbiological disorders) in the pathogenesis 
of this disease [65].  
Recently, there have been reports that the composition of intestinal microorganisms in 
patients with celiac disease is altered compared to healthy people. A reduced number of bacteria 
of the genus Lactobacillus and Bifidobacterium has been demonstrated [66, 67]. In addition, 
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the number of Verrucomicrobia, Parcubacteria and Euryarchaeota was increased and it was 
spositively correlated with TNF-α level and short-chain fatty acids (SCFA) [68]. 
Excessive amounts of Proteobacteria - in particular Neisseria flavescens have also been 
documented. Moreover, in ex vivo studies using CaCo-2 cells (the most widespread cellular 
system imitating human intestinal epithelium), was shown that this bacterium was able to 
escape from the lysosomal compartment and to induce an inflammatory response in dendritic 
cells and in intestinal mucosa explants. In addition, N.flavescens affected the secretion of 
significant amounts of IL-12 and TNF-α [69]. 
The key question remains whether the dysbiosis found in CD patients is the result of a 
rigorous diet, or perhaps it is a factor triggering the onset of celiac disease in genetically 
predisposed individuals. Considering the fact that the dysbiosis of the gastrointestinal 
microbiome may contribute to the induction of many inflammatory signals, the role of 
microorganisms as a potential factor initiating the development of the disease can not be 
neglected. 
 
 
Figure 1. Model depicting how presence of some bacteria in the gut (for example  
P. aeruginosa) can modify gluten peptides which translocate the mucosal barrier more 
efficiently and in a genetically predisposed host, these bacterially modified immunogenic 
peptides can interact with antigen-presenting cells expressing HLA-DQ2 or DQ8. 
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Studies carried out by Caminero et al., seem to confirm this hypothesis. Researchers have 
shown that some microorganisms, such as Pseudomonas aeruginosa, occurring in excessive 
numbers in patients, interact with gluten to produce peptides which activate a strong immune 
response that occurs in the course of celiac disease. The study based on colonizing the digestive 
tract of germ-free C57BL/6 mice with bacteria isolated from the small intestine of patients with 
celiac disease (group 1) or bacteria from healthy people (group 2). Next, after gluten gavage 
into the stomach, the amount of gliadin and proteolytic activities were evaluated in intestinal 
contents. As it turned out, the bacteria isolated from each group of patients, produced distinct 
gluten-degradation patterns in the mouse small intestine. Pseudomonas aeruginosa from 
patients with celiac disease showed elastase activity and produced peptides which translocated 
the intestinal barrier and activated gluten-specific T-lymphocytes (Fig. 1). In contrast, 
Lactobacillus spp. from the duodenum of the control group degraded the immunogenic peptides 
produced by P. aeruginosa, reducing their antigenicity [70].  
It is interesting to note that Van Beurben et al. Van Beurden et al observed symptom relief 
and restoration of duodenal villi after fecal transplantation, which could be attributed to a strong 
microbial compound with celiac disease symptoms [71]. 
Considering the fact that intestinal microbiota is involved in the digestion of gluten 
proteins with the formation of toxic or properly tolerated peptides, maintains the intestinal 
barrier tightness through the release of zonulin and the expression of proteins forming tight 
junctions, promotes the growth and maturation of the intestinal epithelium and regulates the 
activity of the immune system by expression of cytokines and pro- and anti-inflammatory 
proteins,  the role of microorganisms in the pathogenesis of celiac disease should not be 
underestimated. 
 
 
6.  ROLE OF MICROBIOME IN PATHOGENESIS OF INFLAMMATORY BOWEL  
     DISEASE 
 
The pathogenesis of inflammatory bowel disease (IBD) involving two major disease 
entities such as Crohn's disease (CD) and Ulcerative Colitis (UC) is still unknown. It is only 
supposed that immunological, genetic and environmental factors decide about the morbidity. 
In recent years, more and more often, the role of microorganisms in the pathogenesis of IBD 
has been postulated [72, 73]. The role of microorganisms in formation of IBD is confirmed by 
many scientific experiments and clinical observations, among others: exacerbation of the 
disease due to food poisoning or previous stomach infections [74, 75], inability to induce 
intestinal inflammation in experimental animals cultured in germ-free conditions [76], 
alleviation of symptoms of the disease after antibiotic therapy, probiotics supplementation or 
bowel cleansing [76-78] as well as remission induction and alleviation of inflammatory lesions 
after intestinal microbiota transplantation from healthy people [79].  
In recent years, as a result of insightful research on the gastrointestinal microbiome, it has 
been shown that people suffering from IBD are characterized by an imbalance in the 
composition, quantity and functioning of individual microorganisms. 
Extensive research carried out by Frank et al., including 190 resected intestinal tissues 
samples, showed that the gastrointestinal microbiota composition of patients with IBD showed 
significantly reduced colonization by Firmicutes within the Lachnospiraceae family and 
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reduced Bacteroidetes levels in relation to healthy individuals. In addition, among patients, 
there was an increase in the number of Proteobacteria and Actinonobacteria [80]. 
Heidarian et al. demonstrated similar relationships in their studies. Researchers 
documented the decreased number of Bacteroides spp., Faecalibacterium prausnitzii, 
Prevotella spp. and Methanobrevibacterium. Moreover, the intestinal dysbiosis among patients 
with IBD, correlated with the degree of disease activity and higher level of secretion of 
proinflammatory interleukin 8 (IL-8), which excessive production is necessary in initiating and 
maintaining inflammation in IBD [81]. 
Other independent studies have documented that the total contribution of bacteria in 
inflamed intestinal tissue from patients with IBD was different compared to the control group 
and moreover, composition of microorganisms varied depending on the disease entity [82]. The 
tissue from patients with CD was dominated by Streptococcus, whose constituted 78.51% of 
all bacteria, where in the control group the proportion of these microorganisms was negligible 
and consistuted only 3%. On the other hand, patients with UC were primarily characterized by 
colonization of Lactobacillus constituted approximately 90% of the total bacteria, where the 
participation of these microorganisms in gut from healthy people was less than 8%. It is worth 
mentioning that in the control group, the dominant genus was Bifidobacterium, whose 
percentage distribution was 78.95%, while their level in patients was below 10% [82].  
The situation was similar in case of gut colonization of IBD patients by fungi. Intestinal 
tissues collected from inflammatory lesions were characterized by significantly higher diversity 
and richness of gastrointestinal mycobiome than tissues resected from gut without 
inflammation. A huge disproportion was noted among the species of Candida spp., Malassezia 
restricta, Saccharomyces castelli, Cryptococcus neoformans, Gibberella moniliformiss or 
Alternaria brassicicola [83]. It is worth adding that the species diversity and richness of the 
mucosal mycobiome were associated with the expression of IFN-γ, TNF-α or IL-10. Expression 
of IFN-γ and TNF-α was significantly increased in the inflammatory lesions, whereas IL-10 
showed opposite trend. As well as the diversity of the fecal fungal microbiota positively 
correlated with serum C-reactive protein (CRP), Crohn’s Disease activity index (CDAI) [83]. 
On the other hand, analyzes of stool samples (describing gut microbiome), carried out by our 
research team, showed that the gut of children with CD was characterized by significantly higer 
numer of fungi of the genus Candida compared to the control group [84, 85]. Moreover, the 
number of fungal cell was reduced after treatment and it was correlated with a decrease in CDAI 
(Fig. 2). Interesting are the results of study conducted by Hoarau et al., who showed that 
increased colonization of the intestine by Candida tropicalis positively correlated with degree 
of inflammation and increased level of antibodies against Saccharomyces cerevisiae (ASCA) 
which are a biomarker of Crohn’s disease. In addition, the researchers showed that the presence 
of these fungi was associated with an excessive number of Escherichia coli and Serratia 
marcescens. Further immunological studies showed that these microorganisms interacted 
together to forming a strongly adhering to the intestinal mucosa biofilm, inducing an overactive 
inflammatory response which can result in CD symptoms [86]. Besides the commonly found 
dysbiosis among IBD patients, there are also results suggesting that the pathogenesis of these 
diseases entity may be caused by individual microorganism which are often isolated from 
patients and which could participate in the initiation of inflammation of the gastrointestinal 
tract. Until now participation of Mycobacterium paratuberculosis (MAP), Pseudomonas, 
Chlamydia, Yersinia pseudotuberculosis, Listeria monocytogenes, Bacteroides fragilis, 
Escherichia coli, or Bacteroides vulgatus have beed considered [87-89]. 
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Figure 2. Colonization of fungi of the genus Candida in the feces of patients with CD before 
treatment and after TNF-α therapy compared to control group [84]. 
 
 
In particular, the contribution of MAP was one of the most common research objects [90-
92]. This bacterium is significantly more often found among people with IBD compared to 
healthy population [91-93]. Furthemore, considering the fact that MAP has a specific cell wall 
composition and structure containing muramyl dipeptides or mycolic acids, makes this 
bacterium able to promote the induction of an overreactive immune response which may initiate 
the development of inflammatory lesions characteristic of IBD [94]. In addition, mycobacteria 
are able to invade host cells through: growth inside the cells of the infected organism, the ability 
to form granuloma and inhibition of phagosome-lysosome fusion [95]. Another aspect that 
connects MAP with autoimmune diseases is the phenomenon defined as molecular mimicry. It 
is a mechanism, where a bacterial antigen shares structural, functional and serological 
similarities with self-antigens. As a consequence, immune system recognizes self peptides as a 
foreign and it can lead to overreactive immune response against own tissues and promote 
inflammatory lesions [96, 97]. After infection with the mycobacterium, an immune response is 
triggered against the MAP proteins which initiated it, but also against self-proteins resembling 
the attacked pathogen molecule. As a result, after elimination of the bacteria, the immune 
system still induces an inflammatory response against own tissues because it does not 
distinguish autoanitigens from previously eliminated bacterial antigens. Considering the fact, 
that MAP possesses proteins belong to family of heat shock proteins (HSP), showing homology 
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to heat shock proteins found in humans, it is suggested that the mechanism of molecular 
mimicry may be important proccess in initiating some autoimmune diseases, including IBD 
[97, 98]. 
Another bacterium whose participation in the pathogenesis of IBD was often considered 
is Escherichia coli - in particular the adherent-invasive pathotype (AIEC) [99-101]. This strain 
is characterized by the ability to strongly adhere to intestinal epithelial cells as well as to invade 
cells. Moreover, AIEC is ability to survive and to replicate extensively in large vacuoles within 
macrophages without triggering host cell death, and ability to induce the release of large 
amounts of TNF-α and interleukin 23 (IL-23) by infected macrophages [99]. Analysis of 
intestinal biopsies showed that this strain was significantly more common among patients with 
IBD compared to healthy individuals [99, 101]. The additional significance of E.coli in the 
pathogenesis of IBD is also fact that the level of antibodies directed against E. coli flagellin was 
significantly elevated among patients with CD [102]. 
 
 
7.  THE ROLE OF INTESTINAL MICROBIOTA IN CONNECTIVE TISSUE  
     DISEASES 
 
Connective tissue diseases (CTD) are a chronic, inflammatory, autoimmune disorder 
affecting the connective tissue. The most common  CTD include: rheumatoid arthritis, 
systemic lupus erythematosus, systemic sclerosis, Behçet's disease, Sjögren syndrome or mixed 
connective tissue disease. The pathogenesis of these diseases remains unknown, but more and 
more data suggest that CTD is a result of disorders between immunological, environmental, 
genetic and microbiological factors.  While intestinal dysbiosis among patients are commonly 
observed, it is not clear whether changes within the microbiota are a trigger in the development 
of these diseases enity, or only a secondary effect of a long-term disease process [103].  
Disorders in the composition of the intestinal microbiome recently have been a frequent 
topic of interest in research on systemic lupus (SLE). Hevia et al. showed that patients with 
SLE were characterized by a reduced number of Bacteroidetes and Firmicutes compared to 
healthy people [104]. These dependencies were confirmed by He et al. who additionally 
documented increased colonization of the intestine by Rhodococcus, Eggerthella, Klebsiella, 
Prevotella, Eubacterium and Flavonifractor among SLE patients. In turn, number of Dialister 
and Pseudobutyrivibrio was significantly reduced in relation to healthy control group [105]. 
Moreover, Azzouz et al. showed that patients with SLE had an overall 5-fold greater 
representation of Ruminococcus gnavus (RG) of the Lachnospiraceae family, compared to 
healthy people. What's more, the number of these bacteria positively correlated with 
exacerbation of the disease and the presence of antibodies against these bacteria in the blood. 
In particular, the highest levels of serum anti-RG antibodies were detected in patients with 
active nephritis [106]. 
Other independent studies have shown that microorganisms isolated from stool samples 
of SLE patients promoted lymphocyte activation and T helper 17 cells (Th17) differentiation 
from naive CD4+ lymphocytes to a greater extent compared to the microbiota isolated from 
stool samples of control group. Interestingly, the enrichment of microbiota obtained from faeces 
samples of patients with Blautia coccoides, Ruminococcus obeum and Bifidobacterium bifidum 
significantly reduced the Th17/Th1 balance and prevented CD4+ lymphocyte overactivation. 
Further analysis of fecal microbiota showed a negative correlation between the concentration 
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of proinflammatory cytokine IL-17 and the number of Firmicutes in healthy people whereas 
among patients with SLE, these bacteria correlated directly with the serum levels of IFN-γ and 
Th1 lymphocyte. In addition, a negative correlation was showed between the frequency of 
Synergistetes and the anti-double stranded DNA (anti-dsDNA) titers and IL-6 level. In contrast, 
a positive correlation was observed between the numbers of Synergistetes and IgM antibodies 
against phosphorylcholine [107]. The above results show how intestinal microbiota can induce 
changes through the immune system. Moreover, they suggest that probiotic therapy using 
strains inducing T-regulatory cell (Treg) cells may prove effective in restoring balance between 
Treg/Th17/ Th1, whose disorder is found among patients with SLE and plays a key role in the 
induction of inflammation of tissues [107]. 
There are only few studies on the analysis of the composition of microbiota in systemic 
scleroderma (SSc), however, taking into account the fact that one of the most common internal 
organs in the course of SSc is the digestive system whose dysfunction is manifested by 
constipation, abdominal pain, motor disorders and mucosal changes, it is obvious that such 
conditions favor the formation of intestinal dysbiosis. 
Studies conducted by Volkmann et al. seem to confirm the above suppositions. Thus, the 
analysis of the composition of the gastrointestinal microbiota of people with SSc showed that 
patients were characterized by reduced numbers of commensal bacteria, such as 
Faecalibacterium and Clostridium, while increased colonization of opportunistic pathogens, 
such as Fusobacterium and γ-Proteobacteria, was observed compared to healthy controls. 
Interestingly, Bifidobacterium and Lactobacillus, which amount is usually reduced in patients 
with autoimmune, inflammatory diseases, were significantly higher in SSc patients in relation 
to healthy group. It is also worth noting that the severity of gastrointestinal symptoms correlated 
with an increase number of Fusobacterium and the reduction of Bacteroides fragilis [108]. 
Other studies suggest that bacterial overgrowth may promote malabsorption and an impairment 
of intestinal motility in patients with SSc. Parodi et al. showed that small intestinal bacterial 
overgrowth (SIBO) in lactulose breath test (LBT) occured more frequently in SSc patients in 
relation to control group [109]. These dependencies were also confirmed by Marie et al. in 
hydrogen and methane breath test. Moreover, the researchers showed that people with a positive 
glucose hydrogen and methane (H2/CH4) breath test, were characterized by more serious 
symptoms and complications in the digestive tract, compared to people with negative test [110]. 
So far, it has been suggested that changes in intestinal microbiota among SSc patients are 
a secondary result of a long-term disease process, however the appearing results about the 
beneficial effects of antibiotic therapy on symptom alleviation of systemic sclerosis classify 
dysbiosis of the microbiome along with genetic and immunological predisposition as a potential 
factor which may contribute to the pathogenesis of SSc, in particular, to the development of 
intestinal symptoms in SSc patients [109, 110]. 
Recently, the interest around the intestinal microbiome is more and more common in the 
case of Behçet's disease (BD). One of the latest reports showed that Behçet's patients were 
characterized by a decrease number of Roseburia and Subdoligranulum, which was correlated 
with significant decrease of butyrate production. Considering the fact, that butyric acids is able 
to induct differentiation of Treg lymphocytes, their deficiency may contribute to imbalances 
between particular types of lymphocytes and lead to disorders of the immune system, which is 
important in the induction of autoimmune diseases [111]. Other independent studies in patients 
with BD also confirmed intestinal dysbiosis among patients. A significant increase in the 
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number of Bifidobacterium was documented, while the Megamonas and Prevotella species 
occurred in significantly reduced amounts compared to healthy individuals [112]. 
 
 
8.  CONCLUSIONS 
 
The pathogenesis of autoimmune disease remains unknown, which makes it impossible 
to effectively treat and prevent it. As far as it is known that the development of these diseases 
is a results of genetic, immunological and environmental disorders, recently the participation 
of intestinal microbiota in the etiology of these diseases is increasingly considered. The 
possibility of using molecular biology techniques increases the prospect to take a closer look at 
the composition of microorganisms colonizing the digestive tract which creates new cognitive 
abilities of interactions between the microbiome and the host organism. 
Current results provide information about disorders in the composition, quantity and 
functioning of intestinal microorganisms among patients with autoimmune or metabolic 
diseases, however, further research is needed to clarify whether the observed dysbiosis is only 
a secondary result of the ongoing chronic process or maybe it has share in pathogenesis. 
Nevertheless, the incoming results regarding the potential impact of microorganisms on 
the course of the diseases described above, give hope for the implementation of preventive 
measures in the future in order to modify the composition of gastrointestinal microbiota using 
antibiotics, probiotics, bacteriophage therapy or faecal transplantation, which could be a new 
therapeutic target in relieving symptoms these diseases or even prevent their development.  
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